At PC20-FEV1, parameters were moderately decreased, while at end point, test parameters were markedly reduced.
Thus, if noninferiority was established for the primary end point at a one-sided 0.025 significance level, then key secondary end point testing for superiority could proceed in the sequence described previously.
There was some evidence that trials with QoL as primary end point achieved better results than trials with QoL as secondary end point (test for interaction P=0.027 in all trials and P=0.091 in chemotherapy trials), however, this was not confirmed when we further restricted the analysis to placebo-controlled trials.
Both plates were setup to be tested over 2500000 cycles (vertical line = end point of test runs), 2 of 5 antecedent MDF plate design plates (triangle symbol) and 5 of 5 anatomical MDF plate design plates (diamond symbol) failed before reaching the tests end at the various loading levels used (300, 350 and 400 N, antecedent MDF plate and 350,375 and 400 N, anatomical MDF plate plate).
Dosing frequency was not identified as a significant covariate for efficacy and safety end points tested.
However, these discrepancies may be due to myriad differences in CNT forms, experimental methods, and biological end points tested.
Furthermore, we observed differences in curve Hill slopes between congeners for all end points tested [see Supplemental Material, Figure S1 (http://dx.doi.org/10.1289/ehp.1206336)].
In univariate analyses, altered Bax expression was not significantly associated with any of the end points tested either, although there was a trend for treatment failure (RR, 1.30; 95% CI, 0.97 1.73; p = 0.0806).
Secondary confirmatory end points tested were number of treatment-emergent confirmed hypoglycemic episodes, change from baseline in central laboratory measured fasting plasma glucose (FPG), within-subject variability as measured by coefficient of variation, and frequency of participants achieving HbA1c <7% (<53 mmol/mol) without confirmed hypoglycemic episodes.
This might be a "new" end point since the regular chemical testing programme does not include determination of the immunoglobulin D antibody levels to be considered here.
Since genotoxicity is a general prerequisite for the development of malignancy, a great amount of data, collected in several end-point tests, has shown that the exposure to asbestos fibers results in chromosomal aberrations and mutations.
